Rakuten Medical valuation, funding and investors
Rakuten Medical works in precision photoimmunotherapy development, based in San Diego, United States. Founded in 2010, it has about 132 employees.
Pharmaceutical Products Series F
VALUATION · TODAY
$1.62B +0% after Series F
Range $973M – $2.41B · Grade BTODAY
+12 MO
$1.00B
$2.00B
$3.00B
$4.00B
2011
2013
2015
2017
2019
2021
2023
2025
2027
Series C $100M
Series D $166M
Series E $119M
Series F $100M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY132 employees
+8%6m growth
+7%1y growth
+2%2y growth
100
200
300
Data from Jan 2021
Predicted in 1 yr $1.62B +0% vs today
Predicted next raise $197M if a round comes
Winding-down probability 21%
- Last round
- Series F · $100M · Jan 2026
- Valuation at last round
- $1.36B · implied
- Headcount
- 132 · flat
- Grade
- B
- Founded
- 2010
Rakuten Medical valuation today
VCMC values Rakuten Medical at $1.6B today, with a range of $973M to $2.4B and a grade of B. The valuation starts from its last funding round, a Series F round in Jan 2026.
Valuation by date (206 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2011 | $4.67M | $1.70M – $12.8M | $4.69M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2011 | $4.67M | $1.70M – $12.8M | $4.71M (+1%) | before first round | – | unknown | D | 0% |
| 1 Oct 2011 | $4.67M | $1.70M – $12.8M | $4.73M (+1%) | before first round | – | unknown | D | 0% |
| 1 Nov 2011 | $4.67M | $1.70M – $12.8M | $4.75M (+2%) | before first round | – | unknown | D | 0% |
| 1 Dec 2011 | $4.67M | $1.70M – $12.8M | $4.77M (+2%) | before first round | – | unknown | D | 0% |
| 1 Jan 2012 | $4.67M | $1.70M – $12.8M | $4.78M (+2%) | before first round | – | unknown | D | 0% |
| 1 Feb 2012 | $4.67M | $1.70M – $12.8M | $4.80M (+3%) | before first round | – | unknown | D | 0% |
| 1 Mar 2012 | $4.67M | $1.70M – $12.8M | $4.82M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2012 | $4.67M | $1.70M – $12.8M | $4.84M (+4%) | before first round | – | unknown | D | 0% |
| 1 May 2012 | $4.67M | $1.70M – $12.8M | $4.86M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jun 2012 | $4.67M | $1.70M – $12.8M | $4.88M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jul 2012 | $4.67M | $1.70M – $12.8M | $4.90M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2012 | $4.69M | $1.71M – $12.9M | $4.92M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2012 | $4.71M | $1.71M – $12.9M | $4.94M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2012 | $4.73M | $1.72M – $13.0M | $4.96M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2012 | $4.75M | $1.73M – $13.0M | $4.98M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2012 | $4.77M | $1.74M – $13.1M | $4.99M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2013 | $4.78M | $1.74M – $13.1M | $5.01M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2013 | $4.80M | $1.75M – $13.2M | $5.03M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2013 | $4.82M | $1.75M – $13.2M | $5.05M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2013 | $4.84M | $1.76M – $13.3M | $5.07M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2013 | $4.86M | $1.77M – $13.3M | $5.09M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2013 | $4.88M | $1.78M – $13.4M | $5.11M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2013 | $4.90M | $1.78M – $13.5M | $5.13M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2013 | $4.92M | $1.79M – $13.5M | $5.15M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2013 | $4.94M | $1.80M – $13.6M | $5.17M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2013 | $4.95M | $1.80M – $13.6M | $5.19M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2013 | $4.97M | $1.81M – $13.7M | $5.21M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2013 | $4.99M | $1.82M – $13.7M | $5.23M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2014 | $5.01M | $1.83M – $13.8M | $5.25M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2014 | $5.03M | $1.83M – $13.8M | $5.28M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2014 | $5.05M | $1.84M – $13.9M | $5.29M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2014 | $5.07M | $1.85M – $13.9M | $5.32M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2014 | $5.09M | $1.85M – $14.0M | $5.34M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2014 | $5.11M | $1.86M – $14.0M | $5.36M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2014 | $5.13M | $1.87M – $14.1M | $5.38M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2014 | $5.15M | $1.88M – $14.2M | $5.40M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2014 | $5.17M | $1.88M – $14.2M | $5.42M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2014 | $5.19M | $1.89M – $14.3M | $5.44M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2014 | $5.21M | $1.90M – $14.3M | $5.46M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2014 | $5.23M | $1.91M – $14.4M | $5.48M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2015 | $5.25M | $1.91M – $14.4M | $5.51M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $5.28M | $1.92M – $14.5M | $5.53M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $5.29M | $1.93M – $14.5M | $5.55M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $5.32M | $1.93M – $14.6M | $5.57M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $5.34M | $1.94M – $14.7M | $5.59M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $5.36M | $1.95M – $14.7M | $5.61M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $5.38M | $1.96M – $14.8M | $5.64M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $5.40M | $1.97M – $14.8M | $5.78M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $5.42M | $1.97M – $14.9M | $5.94M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $5.44M | $1.98M – $14.9M | $6.09M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $5.46M | $1.99M – $15.0M | $6.26M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $5.48M | $2.00M – $15.1M | $6.42M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $5.51M | $2.00M – $15.1M | $6.60M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.53M | $2.01M – $15.2M | $6.78M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.55M | $2.02M – $15.2M | $6.95M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.57M | $2.03M – $15.3M | $7.14M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.59M | $2.04M – $15.4M | $7.33M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.61M | $2.04M – $15.4M | $7.53M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.64M | $2.05M – $15.5M | $7.72M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.79M | $2.11M – $15.9M | $7.93M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.94M | $2.16M – $16.3M | $8.15M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.10M | $2.22M – $16.8M | $8.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.26M | $2.28M – $17.2M | $8.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.43M | $2.34M – $17.7M | $8.81M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $910M | $597M – $1.8B | $1.2B (+30%) | after a round | – | unknown | B | 0% |
| 1 Sep 2019 | $930M | $597M – $1.8B | $1.2B (+27%) | after a round | – | unknown | B | 0% |
| 1 Oct 2019 | $950M | $597M – $1.8B | $1.2B (+24%) | after a round | – | unknown | B | 0% |
| 1 Nov 2019 | $972M | $597M – $1.8B | $1.2B (+22%) | after a round | – | unknown | B | 0% |
| 1 Dec 2019 | $993M | $597M – $1.8B | $1.2B (+19%) | after a round | – | unknown | B | 0% |
| 1 Jan 2020 | $1.0B | $597M – $1.8B | $1.2B (+16%) | after a round | – | unknown | B | 0% |
| 1 Feb 2020 | $1.0B | $597M – $1.8B | $1.2B (+14%) | after a round | – | unknown | B | 0% |
| 1 Mar 2020 | $1.1B | $597M – $1.8B | $1.2B (+11%) | after a round | – | unknown | B | 0% |
| 1 Apr 2020 | $1.1B | $597M – $1.8B | $1.2B (+9%) | after a round | – | unknown | B | 0% |
| 1 May 2020 | $1.1B | $597M – $1.8B | $1.2B (+7%) | after a round | – | unknown | B | 0% |
| 1 Jun 2020 | $1.1B | $597M – $1.8B | $1.2B (+4%) | after a round | – | unknown | B | 0% |
| 1 Jul 2020 | $1.2B | $597M – $1.8B | $1.2B (+2%) | after a round | – | unknown | B | 0% |
| 1 Aug 2020 | $1.2B | $596M – $1.8B | $1.2B (0%) | after a round | – | unknown | B | 0% |
| 1 Sep 2020 | $1.2B | $569M – $1.8B | $1.2B (0%) | after a round | – | unknown | B | 0% |
| 1 Oct 2020 | $1.2B | $544M – $1.8B | $1.2B (0%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $1.2B | $519M – $1.8B | $1.2B (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2020 | $1.2B | $496M – $1.8B | $1.2B (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2021 | $1.2B | $474M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Feb 2021 | $1.2B | $452M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Mar 2021 | $1.2B | $434M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Apr 2021 | $1.2B | $414M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 May 2021 | $1.2B | $396M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Jun 2021 | $1.2B | $378M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Jul 2021 | $1.2B | $361M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 1 Aug 2021 | $1.2B | $327M – $1.8B | $1.2B (0%) | after a round | 200 | unknown | C | 0% |
| 3 Aug 2021 | $1.9B | $1.3B – $3.5B | $2.5B (+30%) | after a round | 200 | unknown | B | 0% |
| 1 Sep 2021 | $1.9B | $1.3B – $3.5B | $2.5B (+27%) | after a round | 200 | unknown | B | 0% |
| 1 Oct 2021 | $2.0B | $1.3B – $3.5B | $2.5B (+25%) | after a round | 200 | unknown | B | 0% |
| 1 Nov 2021 | $2.0B | $1.3B – $3.5B | $2.5B (+22%) | after a round | 200 | unknown | B | 0% |
| 1 Dec 2021 | $2.1B | $1.3B – $3.5B | $2.5B (+19%) | after a round | 200 | unknown | B | 0% |
| 1 Jan 2022 | $2.1B | $1.3B – $3.5B | $2.5B (+17%) | after a round | 200 | unknown | B | 0% |
| 1 Feb 2022 | $2.2B | $1.3B – $3.5B | $2.5B (+14%) | after a round | 200 | unknown | B | 0% |
| 1 Mar 2022 | $1.9B | $1.3B – $2.8B | $1.8B (-10%) | after a round | 170 | down | B | 81% |
| 1 Apr 2022 | $2.0B | $1.3B – $2.8B | $1.7B (-12%) | after a round | 170 | down | B | 81% |
| 1 May 2022 | $2.0B | $1.3B – $2.8B | $1.7B (-14%) | after a round | 170 | down | B | 81% |
| 1 Jun 2022 | $2.0B | $1.3B – $2.8B | $1.7B (-16%) | after a round | 170 | down | B | 81% |
| 1 Jul 2022 | $2.0B | $1.3B – $2.8B | $1.6B (-17%) | after a round | 170 | down | B | 81% |
| 1 Aug 2022 | $2.0B | $1.3B – $2.9B | $1.7B (-18%) | after a round | 170 | unknown | B | 75% |
| 1 Sep 2022 | $2.0B | $1.3B – $2.9B | $1.6B (-19%) | after a round | 170 | unknown | B | 69% |
| 1 Oct 2022 | $2.0B | $1.2B – $3.0B | $1.7B (-18%) | after a round | 170 | unknown | B | 63% |
| 1 Nov 2022 | $2.0B | $1.2B – $3.1B | $1.7B (-16%) | after a round | 170 | unknown | B | 58% |
| 1 Dec 2022 | $2.0B | $1.1B – $3.1B | $1.7B (-15%) | after a round | 170 | unknown | B | 54% |
| 1 Jan 2023 | $2.0B | $1.0B – $3.1B | $1.8B (-14%) | after a round | 170 | unknown | B | 49% |
| 1 Feb 2023 | $2.1B | $1.0B – $3.2B | $1.8B (-13%) | after a round | 160 | flat | B | 45% |
| 1 Mar 2023 | $2.1B | $959M – $3.2B | $1.8B (-12%) | after a round | 160 | flat | C | 42% |
| 1 Apr 2023 | $2.1B | $915M – $3.3B | $1.8B (-12%) | after a round | 160 | flat | C | 38% |
| 1 May 2023 | $2.1B | $875M – $3.3B | $1.9B (-11%) | after a round | 160 | flat | C | 35% |
| 1 Jun 2023 | $2.1B | $835M – $3.3B | $1.9B (-10%) | after a round | 160 | flat | C | 32% |
| 1 Jul 2023 | $2.1B | $798M – $3.3B | $1.9B (-10%) | after a round | 160 | flat | C | 30% |
| 1 Aug 2023 | $2.1B | $761M – $3.4B | $1.9B (-10%) | after a round | 160 | flat | C | 30% |
| 1 Sep 2023 | $2.1B | $697M – $3.4B | $1.9B (-11%) | after a round | 160 | unknown | C | 28% |
| 1 Oct 2023 | $2.1B | $663M – $3.4B | $1.9B (-10%) | after a round | 160 | unknown | C | 26% |
| 1 Nov 2023 | $1.6B | $630M – $3.3B | $1.2B (-26%) | after a round | 140 | down | C | 67% |
| 1 Dec 2023 | $1.6B | $600M – $3.3B | $1.2B (-26%) | after a round | 140 | down | C | 67% |
| 1 Jan 2024 | $1.6B | $570M – $3.3B | $1.1B (-27%) | after a round | 140 | down | C | 67% |
| 1 Feb 2024 | $1.5B | $542M – $3.3B | $1.1B (-27%) | after a round | 140 | down | C | 67% |
| 1 Mar 2024 | $1.5B | $517M – $3.4B | $1.1B (-28%) | after a round | 140 | down | C | 67% |
| 7 Mar 2024 | $1.5B | $977M – $2.5B | $1.6B (+9%) | after a round | 140 | down | B | 67% |
| 1 Apr 2024 | $1.5B | $977M – $2.3B | $1.5B (-1%) | after a round | 130 | down | B | 97% |
| 1 May 2024 | $1.5B | $977M – $2.3B | $1.4B (-3%) | after a round | 130 | down | B | 97% |
| 1 Jun 2024 | $1.5B | $977M – $2.3B | $1.4B (-5%) | after a round | 130 | down | B | 97% |
| 1 Jul 2024 | $1.5B | $977M – $2.3B | $1.4B (-7%) | after a round | 130 | down | B | 97% |
| 1 Aug 2024 | $1.5B | $977M – $2.3B | $1.4B (-8%) | after a round | 130 | flat | B | 89% |
| 1 Sep 2024 | $1.5B | $977M – $2.4B | $1.4B (-8%) | after a round | 130 | flat | B | 82% |
| 1 Oct 2024 | $1.5B | $977M – $2.4B | $1.4B (-8%) | after a round | 130 | flat | B | 76% |
| 1 Nov 2024 | $1.6B | $977M – $2.5B | $1.4B (-9%) | after a round | 130 | flat | B | 70% |
| 1 Dec 2024 | $1.6B | $977M – $2.5B | $1.4B (-9%) | after a round | 130 | flat | B | 64% |
| 1 Jan 2025 | $1.6B | $977M – $2.5B | $1.5B (-10%) | after a round | 130 | flat | B | 59% |
| 1 Feb 2025 | $1.7B | $977M – $2.6B | $1.5B (-11%) | after a round | 130 | flat | B | 54% |
| 1 Mar 2025 | $1.7B | $977M – $2.6B | $1.5B (-12%) | after a round | 130 | flat | B | 50% |
| 1 Apr 2025 | $1.7B | $939M – $2.6B | $1.5B (-13%) | after a round | 130 | flat | B | 46% |
| 1 May 2025 | $1.7B | $896M – $2.7B | $1.5B (-12%) | after a round | 130 | flat | B | 42% |
| 1 Jun 2025 | $1.7B | $854M – $2.7B | $1.5B (-11%) | after a round | 130 | flat | B | 39% |
| 1 Jul 2025 | $1.7B | $816M – $2.7B | $1.5B (-10%) | after a round | 130 | flat | C | 36% |
| 1 Aug 2025 | $1.7B | $778M – $2.7B | $1.5B (-10%) | after a round | 130 | flat | C | 33% |
| 1 Sep 2025 | $1.7B | $733M – $2.7B | $1.5B (-9%) | after a round | 123 | flat | C | 30% |
| 1 Oct 2025 | $1.7B | $700M – $2.8B | $1.5B (-9%) | after a round | 123 | flat | C | 30% |
| 1 Nov 2025 | $1.6B | $663M – $2.7B | $1.4B (-12%) | after a round | 121 | flat | C | 38% |
| 1 Dec 2025 | $1.6B | $634M – $2.7B | $1.4B (-12%) | after a round | 122 | flat | C | 38% |
| 1 Jan 2026 | $1.6B | $604M – $2.7B | $1.4B (-12%) | after a round | 122 | flat | C | 38% |
| 8 Jan 2026 | $1.4B | $956M – $2.3B | $1.6B (+17%) | after a round | 122 | flat | B | 38% |
| 1 Feb 2026 | $1.4B | $956M – $2.3B | $1.6B (+16%) | after a round | 122 | flat | B | 35% |
| 1 Mar 2026 | $1.4B | $956M – $2.3B | $1.6B (+14%) | after a round | 122 | flat | B | 35% |
| 1 Apr 2026 | $1.4B | $956M – $2.3B | $1.6B (+12%) | after a round | 122 | flat | B | 35% |
| 1 May 2026 | $1.4B | $956M – $2.3B | $1.6B (+9%) | after a round | 122 | flat | B | 35% |
| 1 Jun 2026 | $1.5B | $968M – $2.3B | $1.6B (+8%) | after a round | 129 | flat | B | 32% |
| 1 Jul 2026 | $1.5B | $968M – $2.3B | $1.6B (+7%) | after a round | 129 | flat | B | 30% |
| 1 Aug 2026 | $1.5B | $968M – $2.4B | $1.6B (+5%) | after a round | 129 | flat | B | 27% |
| 1 Sep 2026 | $1.6B | $968M – $2.4B | $1.6B (+3%) | after a round | 129 | flat | B | 25% |
| 1 Oct 2026 | $1.6B | $973M – $2.4B | $1.6B (+1%) | after a round | 132 | flat | B | 23% |
| 24 Oct 2026 | $1.6B | $973M – $2.4B | $1.6B (0%) | after a round | 132 | flat | B | 21% |
Key facts about Rakuten Medical
- Founded
- 2010
- Headquarters
- San Diego, United States
- Employees
- about 132 +9% in a year
- Total raised
- $485M
- Funding rounds
- 4
- Last round
- Series F Jan 2026
Rakuten Medical was founded in 2010 by Mickey Mikitani and Nobuo Kanazawa.
Rakuten Medical funding history
Rakuten Medical has 4 funding rounds on record, from Jul 2019 to Jan 2026, $485M in total. None disclosed a valuation.
Series F 7 Jan 2026
Led by Taiwania Capital; with Daiwa Securities Group, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Holdings, Rakuten Group, Inc., QF Capital, Sumitomo Mitsui Trust Bank.
Sources: rakuten-med.com, f4.fund, businessofsandiego.substack.com and 3 more
$100M
Series E 6 Mar 2024
With Hikma Ventures, Mizuho Bank, Ltd., Dai-ichi Life Insurance Company, Limited, SBI Holdings, Rakuten Group, Inc..
Sources: rakuten-med.com, geneonline.com, mofo.com
$119M
Series D 2 Aug 2021
Led by General Catalyst; with Rakuten Group, SBI Holdings.
Sources: finsmes.com, prnewswire.com, buttondown.com
$166M
Series C 31 Jul 2019
With Rakuten, Inc..
Sources: prnewswire.com, global.rakuten.com, rakuten-med.com and 1 more
$100M
Rakuten Medical investors
17 investors have backed Rakuten Medical; General Catalyst and Taiwania Capital led at least one round.
- General Catalyst lead
- Rakuten Group, Inc. 2 rounds
- Dai-ichi Life Insurance Company, Limited
- Mitsui Sumitomo Insurance
- Mizuho Bank, Ltd.
- Nexus CVC
- OEP Group
- Rakuten Group
- Rakuten, Inc.
- Sumitomo Mitsui Banking
- Sumitomo Mitsui Trust Bank
What Rakuten Medical does
Rakuten Medical works in pharmaceutical products, with 12 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Rakuten Medical, Inc. is a United States biotechnology company engaged in precision, cell-targeting photoimmunotherapy. The company develops and advances treatments for cancer, including drug-device combinations and investigational technologies, and conducts clinical trials in Japan, the United States, and Taiwan. Rakuten Medical also operates as a manufacturer and distributor of its proprietary technologies, with a global presence through affiliates and service providers in Japan, Taiwan, Switzerland, and India.
Description from Veridion's company data.
Products and services
- Precision Photoimmunotherapy Development
- Cell-Targeting Drug Discovery
- Drug-Device Combination Development
- Oncology Drug Clinical Trials
- Combination Therapy Development
- Head and Neck Cancer Treatment Development
- Solid Tumor Treatment Development
- Liver Metastasis Treatment Development
- IR700 Dye Commercialization
- Academic Dye Access Services
- Healthcare Ecosystem Development
- Cancer Treatment Innovation Services
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Cell-Targeting Photoimmunotherapy
- Drug-Device Combination for Local Illumination and Drug Activation
- Light-Activatable Dye Conjugated to Cell-Targeting Moiety
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 325412 Pharmaceutical Preparation Manufacturing 100% match
Questions about Rakuten Medical
What is Rakuten Medical worth?
Valuation $1.6B (range $973M to $2.4B), as of 24 Oct 2026.
Has Rakuten Medical raised money?
Rakuten Medical has 4 funding rounds on record, from Jul 2019 to Jan 2026, $485M in total. None disclosed a valuation.
Who has invested in Rakuten Medical?
General Catalyst, Taiwania Capital, SBI Holdings, Rakuten Group, Inc., ABIES Capital and Dai-ichi Life Insurance Company, Limited, and 11 more. Lead investors include General Catalyst and Taiwania Capital.
How many people work at Rakuten Medical?
About 132, up 9% over the last year. Headcount fell from 200 in Jan 2021 to 132 in Sep 2026.
What does Rakuten Medical do?
Rakuten Medical works in pharmaceutical products, with 12 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are precision photoimmunotherapy development, cell-targeting drug discovery and drug-device combination development.
When was Rakuten Medical founded, and where is it based?
Rakuten Medical was founded in 2010 and is based in San Diego, United States. It has about 132 employees, up 9% over the last year.